Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Headquarters

CN

CEO

Daping Liu

Listed since

Jan 16, 2014

Employees

8,878